Special Issue

New Insights into Targeted Therapy and Immunotherapy for Non-Small-Cell Lung Cancer

Message from the Guest Editor

Over the past two decades, treatment for lung cancer has advanced dramatically. Two treatments that have made significant progress are molecular targeted therapy and immunotherapy. They have taken over the leading role from platinum drugs, leading to remarkable long-term survival. This Special Issue will accept a variety of manuscripts to address issues related to advances in lung cancer treatment, including original articles (clinical and basic studies) and reviews. For reviews, instead of immunotherapy as a whole, it is advisable to focus on more specific topics such as immunotherapy for the elderly, perioperative immunotherapy, ICI readministration, patients with autoimmune diseases, anti-PD-1 vs. anti-PD-L1, etc. As for molecular targeted therapy, not only EGFR and ALK but also low-frequency genetic abnormalities such as BRAF and MET can be categorized, and comparisons of multi-gene testing methods, TKI readministration, etc., are also acceptable. Topics such as image findings, artificial intelligence, or statistical analysis methods are also acceptable.

Guest Editor

Dr. Nobuhiro Kanaji

Department of Internal Medicine, Division of Hematology, Rheumatology, and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

Deadline for manuscript submissions

closed (31 March 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/210249

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

